Genmab — Oktober 2019

[peter12]

Det er lidt af en milestone

[peter12]

Men det er efter 20 programmer ....

[Sukkeralf]

Fra årsregnskabet: As of December 31, 2018, Janssen had exercised 14
licenses under this collaboration. No further options remain
for use by Janssen.

[E_L]

ok, thanks for updating me here

[E_L]

so the difference between the 14 and 20? maybe to do with an expiration time?

[Sukkeralf]

Im not sure how to understand that last sentence "No further options remain for use by Janssen".

[Sukkeralf]

It could fit with a 5 year timeline to start the programs - but lets ask Jan at the coming Q&A

[Sukkeralf]

Maybe a coincidence but Janssen signed at deal for 6 programs with Zymeworks end 2017 or beginning of 2018

[Sukkeralf]

Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

(www.fiercebiotech.com)

[E_L]

ah. ok. no that is not coincidence lol. Will you ask then?

[Sukkeralf]

jep

[E_L]

KEYTRUDA Sales Grew 62% to $3.1 Billion. For the quarter that is...not for the year...

[Sukkeralf]

E L - just asked Andrew and Janssen has activated 14 of 20 programs and its not possible to activate the last 6

[Sukkeralf]

So that kind of fits with the Zymeworks deal !!

[peter12]

But no milestone for "all" activated ?

[Sukkeralf]

Yes yes milestones according to the licensing deal for the 14 activated

[Sukkeralf]

and royalty if they reach the marked

[peter12]

Ok thanks

[Sukkeralf]

We know 1 has failed in the clinic and we have 6 active in the clinic right now - so thats half of the 14 that reached the clinic. i would guess thats quite good.........and if we are lucky still one or maybe two could still enter the clinic.

[Sukkeralf]

And and average of maybe 10-20 phase one antibody candidates gets all the way - so lets hope for 2 Janssen bispecifics on the marked